Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

PHASE2CompletedINTERVENTIONAL
Enrollment

647

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

March 24, 2025

Study Completion Date

March 28, 2025

Conditions
Migraine
Interventions
DRUG

BHV-2100

BHV-2100 75mg

DRUG

BHV-2100

BHV-2100 150 mg

DRUG

Placebo

matching placebo

Trial Locations (60)

10017

Fieve Clinical Research, Inc., New York

13850

Velocity Clinical Research, Vestal, Vestal

14609

Rochester Clinical Research, Rochester

15410

Preferred Primary Care Physicians, Uniontown

20854

Velocity Clinical Research, Rockville, Rockville

22911

Charlottesville Medical Research, Charlottesville

27408

PharmQuest Life Sciences, Greensboro

27609

Accellacare of Raleigh, Raleigh

29204

Velocity Clinical Research, Columbia, Columbia

29405

Coastal Carolina Research Center, North Charleston

30328

NeuroTrials Research, Inc., Atlanta

31406

Velocity Clinical Research, Savannah, Savannah

32055

WR-MSRA (Multi-Specialty Research Associates), Lake City

32258

Green Leaf Clinical Trials, Jacksonville

33014

Ideal Research, Pembroke Pines

33126

AppleMed Research Group, Miami

33407

Premier Research Instiute, West Palm Beach

33613

ForCare Clinical Research, Tampa

37067

KCA Neurology, Franklin

40213

L-MARC Research Center, Louisville

45424

Hometown Urgent Care and Research, Dayton

47334

Quest Research Institute, Farmington Hills

48112

Michigan Head Pain and Neurological Institute, Ann Arbor

50265

Integrated Clinical Trials Services, West Des Moines

51106

Velocity Clinical Research, Sioux City, Sioux City

55402

Clinical Research Institute, Minneapolis

60422

Healthcare Research Network II, LLC, Flossmoor

60657

Chicago Headache Center & Research Center, Chicago

63303

StudyMedrix Research, City of Saint Peters

64114

Alliance for Multispecialty Research - Kansas City, Kansas City

65807

Clinvest Research, Springfield

66210

Collective Medical Research, Overland Park

70043

Crescent City Headache & Neurology, Chalmette

70115

DelRicht Research, New Orleans

73034

OK Clinical Research, LLC, Edmond

75057

Epic Clinical Research, Lewisville

75230

Zenos Clinical Research, Dallas

77081

DM Clinical Research - Belliare, Houston

77375

DM Clinical Research - Tomball, Tomball

77566

Red Star Research, LLC, Lake Jackson

78732

FutureSearch Trials of Neurology, Austin

84088

Velocity Clinical Research, Salt Lake City, West Jordan

85286

MD First Research, Gilbert

87102

Albuquerque Clinical Trials, Albuquerque

89118

WR-CRNC (Wake Research), Las Vegas

90048

Clinical Research Institute, Los Angeles

90720

Cenexel CNS Los Alamitos, Los Alamitos

91316

WR-PRI, LLC (Encino), Encino

92506

Cenexel CIT IE, Riverside

92660

WR-PRI, LLC (Newport Beach), Newport Beach

98007

Northwest Clinical Research Center, Bellevue

98104

Seattle Clinical Research Center, Seattle

06511

Hasbani Neurology, New Haven

06905

Ki Health Partners DBA/ New England Institute for Clinical Research, Stamford

02131

Boston Clinical Trials, Boston

02035

Neurology Center of New England PC, Foxborough

02451

MedVadis Research Corp, Waltham

01581

Mass Institute of Clinical Research, Westborough

03801

ActivMed Practices & Research-Portsmouth/Pease, Portsmouth

02818

Velocity Clinical Research, Providence, East Greenwich

Sponsors
All Listed Sponsors
lead

Biohaven Therapeutics Ltd.

INDUSTRY

NCT06603623 - Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine | Biotech Hunter | Biotech Hunter